We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

66 hedge funds and large institutions have $168M invested in Catalyst Pharmaceutical in 2015 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

107% more capital invested

Capital invested by funds: $81.3M → $168M (+$87.1M)

58% more call options, than puts

Call options by funds: $128K | Put options by funds: $81K

43% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 14

32% more funds holding

Funds holding: 50 → 66 (+16)

Holders
66
Holders Change
+16
Holders Change %
+32%
% of All Funds
1.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
20
Reduced
14
Closed
8
Calls
$128K
Puts
$81K
Net Calls
+$47K
Net Calls Change
-$46K

Top Buyers

1
CCM
Consonance Capital Management
New York
+$17.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$11.1M
3
BC
Broadfin Capital
New York
+$6.07M
4
PA
Perceptive Advisors
New York
+$4.33M
5
BBA
Baker Bros. Advisors
New York
+$3.06M

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$2.9M
2
PCA
Private Capital Advisors
Connecticut
-$2.46M
3
VAM
Visium Asset Management
New York
-$2.21M
4
ACA
Avoro Capital Advisors
New York
-$1.64M
5
GTC
Ghost Tree Capital
New York
-$743K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$539K +$448K +124,399 New
EMFAT
27
Emerald Mutual Fund Advisers Trust
Pennsylvania
$533K +$541K +150,000 New
BCM
28
BlueCrest Capital Management
Jersey
$516K +$429K +119,054 New
CA
29
Corrado Advisors
New Jersey
$458K +$381K +105,700 New
Goldman Sachs
30
Goldman Sachs
New York
$446K +$304K +84,222 +450%
TCM
31
Tanaka Capital Management
New York
$438K -$96.6K -26,800 -19%
Northern Trust
32
Northern Trust
Illinois
$418K -$1.89K -525 -0.5%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$399K -$144 -40 -0%
ARTA
34
A.R.T. Advisors
New York
$398K +$202K +56,058 +156%
WPP
35
Whalerock Point Partners
Rhode Island
$367K +$189K +52,500 +162%
Millennium Management
36
Millennium Management
New York
$357K +$297K +82,372 New
Bank of America
37
Bank of America
North Carolina
$278K -$75.7K -21,000 -25%
PSC
38
Piper Sandler & Co
Minnesota
$217K +$180K +50,000 New
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$201K – – –
State Street
40
State Street
Massachusetts
$193K – – –
CPA
41
Cowen Prime Advisors
New York
$186K – – –
Wells Fargo
42
Wells Fargo
California
$164K -$192K -53,200 -58%
Citadel Advisors
43
Citadel Advisors
Florida
$153K -$10.8K -2,999 -8%
Stifel Financial
44
Stifel Financial
Missouri
$152K +$126K +35,000 New
AL
45
Agran Libbie
California
$147K +$50.5K +14,000 +70%
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$138K – – –
FANJ
47
Financial Architects (New Jersey)
New Jersey
$130K – – –
Verition Fund Management
48
Verition Fund Management
Connecticut
$100K +$83.1K +23,050 New
Renaissance Technologies
49
Renaissance Technologies
New York
$92K +$76.5K +21,227 New
CAS
50
CTC Alternative Strategies
Illinois
$77.9K +$64.9K +18,000 New
1
2
3

CPRX Hedge Fund Activity: Q1 2015 in Review

66 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2015, worth a combined $168M — up 107% from $81.3M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CPRX positions and 8 closed out — a net gain of 16 holders — while 20 added to existing stakes and 14 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $17.5M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.9M sold.

  • 66 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2015, up from 50 in Q4 2014.
  • Funds reported $168M of Catalyst Pharmaceutical stock for Q1 2015, up 107% quarter-over-quarter.
  • 24 funds opened new Catalyst Pharmaceutical positions in Q1 2015 and 8 closed out, a net change of +16 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2015 was Consonance Capital Management, an estimated $17.5M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2015 was Opaleye Management, an estimated $2.9M sold.

Based on aggregated 13F filings for Q1 2015.